|
SVR all, n (%)
|
18/36 (50)
|
27/52 (52)
|
0.860
|
|
RVR, n (%)
|
9/36 (25)
|
17/52 (32)
|
0.440
|
|
EVR, n (%)
|
6/36 (17)
|
7/52 (13)
|
0.677
|
|
SVR GT 1, n (%)
|
5/15 (33)
|
11/27 (40)
|
0.626
|
|
SVR GT 2, n (%)
|
1/2 (50)
|
7/8 (87)
|
0.356
|
|
SVR GT 3, n (%)
|
9/14 (64)
|
7/12 (58)
|
0.756
|
|
SVR GT 4, n (%)
|
1/1 (100)
|
2/4 (50)
|
0.600
|
|
GT unknown, n (%)
|
2/36 (5)
|
0/52 (0)
|
0.809
|
|
SVR GT 1 + 4, n (%)
|
6/16 (37)
|
13/31 (41)
|
0.770
|
|
SVR GT 2 + 3, n (%)
|
10/16 (62)
|
14/20 (70)
|
0.636
|
|
Discontinuation of therapy, n (%)
|
3/36 (12)
|
4/52 (7)
|
0.305
|
|
Breakthrough infection, n (%)
|
1/36 (2)
|
0/52
|
0.410
|
|
Non-response, n (%)
|
5/36 (13)
|
3/52 (5)
|
0.130
|
|
Relapse, n (%)
|
7/36 (19)
|
9/52 (17)
|
0.482
|
|
Unknown, n (%)
|
2/36 (5)
|
9/52 (17)
|
0.105
|
|
SVR HAART treated patients, n (%)
|
14/29 (48)
|
n.a.
|
n.a.
|
|
SVR non-HAART treated patients, n (%)
|
4/7 (57)
|
n.a.
|
n.a.
|
|
SVR CD4 Nadir > 200/μl, n (%)
|
9/18 (50)
|
n.a.
|
n.a.
|
|
SVR CD4 Nadir < 200/μl, n (%)
|
9/18 (50)
|
n.a.
|
n.a.
|
